




# CEE UPDATES

December 2025

## NEW IMPACT STORIES PUBLISHED



Two new stories have been added to ACE's "**Voices to Impact**" digital flipbook, demonstrating the meaningful contributions of patients and carers to ACE's work and other patient involvement initiatives across the Asia Pacific region:

Find out more



***Unlocking the Impact of Patient Involvement in HTA in the Asia Pacific*** features insights and illustrations on patient involvement in HTA across the Asia Pacific region, captured during the 12th HTAsiaLink 2025 Pre-Conference Patient Workshop in August 2025.



Includes videos of workshop participants sharing their insights



***Co-creation in Practice*** features reflections from local patient groups on co-developing factsheets with ACE on treatments for type 2 diabetes.



## ANNUAL CALL FOR TOPICS

ACE conducts technical evaluations to assess the effectiveness, safety, and value of health technologies (such as drugs, vaccines, and medical devices) to inform the Ministry of Health (MOH) advisory committees when they make funding recommendations.

The **annual call for topics** is still open for patients, carers and patient organisations to suggest which drugs or medical devices ACE should evaluate for different health conditions. Read our [factsheet](#) to find out the key steps of the application process.

Topic suggestions should be submitted by **31 January 2026**. Contact the CEE team or your patient organisation for an application form.





# 20

## Plain English summaries published since September 2025



Find out more



### New:

- Advanced hybrid closed loop system for people with type 1 diabetes mellitus
- Datopotamab deruxtecan for previously treated HR-positive, HER2-negative advanced breast cancer
- Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer
- Gene therapy for spinal muscular atrophy
- Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
- Sotorasib for previously treated KRAS G12C-mutated advanced non-small-cell lung cancer
- Sucroferric oxyhydroxide for treating hyperphosphataemia
- Talazoparib in combination with enzalutamide for treating homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer
- Toripalimab for treating recurrent or metastatic nasopharyngeal carcinoma

Plain English summaries (PES) provide brief information about the health technologies and conditions that have been evaluated by ACE and describe the key funding recommendations made by the MOH advisory committees.

### Updated:

- Afibercept and faricimab for treating diabetic macular oedema and age-related macular degeneration
- Botulinum toxin A for treating adults with focal spasticity of the lower limbs associated with stroke
- Botulinum toxin A for treating blepharospasm or hemifacial spasm
- Botulinum toxin A for treating cervical dystonia
- Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy
- Continuous glucose monitoring systems for children and adults with type 1, monogenic or pancreatogenic diabetes mellitus
- Dostarlimab for treating primary advanced or recurrent endometrial cancer
- Epcoritamab for previously treated relapsed or refractory diffuse large B-cell lymphoma
- Finerenone for treating chronic kidney disease and protein in the urine associated with type 2 diabetes
- Sacituzumab govitecan for previously treated HR-positive, HER2-negative advanced breast cancer
- Selexipag for treating pulmonary arterial hypertension

## PATIENT FACTSHEETS

# 4

**Patient factsheets published since September 2025**

- Injectable treatments for osteoporosis **(new)**
- Treatments for unresectable hepatocellular carcinoma **(new)**
- Biosimilars: a safe, effective and more affordable option for patients **(updated)**
- Injectable and newer oral treatments for preventing migraine **(updated)**



Find out more



## PATIENT INPUT

Over

# 50

**Patient responses were gathered for topics presented to the MOH advisory committees in June 2025**



The effort put in by patients to share their experiences is appreciated and every input is valuable to ACE and MOH. The CEE team notifies patient organisations of the advisory committees' funding recommendations after each meeting and provides feedback on which information provided by patients was most helpful to inform the committees' deliberations. The CEE team also invites suggestions on how the patient involvement processes can be improved through this [link](#).

*Season's Greetings*

The CEE team would like to thank the ACE Consumer Panel and all local patient organisations for their contributions and support in 2025. We look forward to continuing working with you to advance meaningful patient involvement in healthcare decision-making.

Wishing everyone a joyful holiday season, and a healthy, fulfilling new year ahead!



The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidelines and education.

The Consumer Engagement and Education (CEE) team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors.

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore.

**Published on 16 December 2025.** To find out more about ACE, scan the QR code or visit [www.ace-hta.gov.sg](http://www.ace-hta.gov.sg). You can also follow us on social media at:

